Skin and soft tissue infections are more common in children with Crohn’s disease, especially those receiving combination ...

SHANGHAI, Jan 27 (Reuters) - German drugmaker Boehringer Ingelheim will license an experimental inflammatory bowel disease ...

Halozyme is Monday's IBD Stock Of The Day. Shares are flirting with a pair of entries after the drug delivery expert issued a ...

LGBTQ+ individuals with inflammatory bowel disease experience multiple gaps and inequities in care when managing their ...

A biotech pioneer introduces innovative diagnostic kits designed to slash costs, speed up results, and support timely ...

For decades, patients with inflammatory bowel disease have reported a familiar and frustrating pattern: periods of intense ...

A hidden immune cascade linking the gut and bone marrow may explain how IBD turns inflammation into colon cancer.

Boehringer Ingelheim has added another drug to its immunology pipeline, licensing an inflammatory bowel disease (IBD) ...

Appointments strengthen Palisade Bio's clinical strategy as PALI-2108 advances toward Phase 2 development in ulcerative colitis and fibrostenotic Crohn's disease, with a Phase 2 UC IND submission ...

Designed to provide broad exposure to the Investment Grade Corporate Bond ETFs category of the market, the Inspire Corporate Bond ETF (IBD) is a smart beta exchange traded fund launched on 07/10/2017.

Among patients with IBD in self reported clinical remission, habitual meat intake may affect the risk for flares in those with ulcerative colitis, but not in those with Crohn's disease.

Boehringer Ingelheim has penned a 1.05 billion euro ($1.26 billion) biobucks deal for Simcere’s preclinical inflammatory bowel disease (IBD) bispecific antibody. | Boehringer Ingelheim has penned a 1.